FDA Draft Guidance on Alternatives to Animal Testing in Drug Development

Wed, 18 Mar 2026 15:34:52 +0000
Pharmaceuticals

The FDA has issued draft guidance to assist drug developers in validating new approach methodologies (NAMs) as alternatives to animal testing in drug development. This guidance supports the FDA's roadmap to reduce animal testing and bring safe, effective drugs to market sooner.